TY - JOUR
T1 - Mild cognitive impairment due to Alzheimer disease
T2 - Contemporary approaches to diagnostics and pharmacological intervention
AU - Bachurin, Sergey O.
AU - Gavrilova, Svetlana I.
AU - Samsonova, Anna
AU - Barreto, George E.
AU - Aliev, Gjumrakch
N1 - Publisher Copyright:
© 2017
PY - 2018/3
Y1 - 2018/3
N2 - Alzheimer disease (AD) and related forms of dementia are among the main medical and social problems in the economically developed countries. It is connected with significant increase in human life span in these regions and with the absence of efficient medicines for treatment and prevention of such diseases. Lack of positive results in the developing of novel drugs for AD treatment stimulates special attention on problem of early diagnosis and drug discovery for pharmacotherapy on the very early stages of dementia, in particular, on mild cognitive impairments (MCI) due to AD. Here we review the state of art in the field of MCI diagnostics and analyze the data on the pharmacological agents developed for MCI treatment, which currently are in preclinical and clinical trials. The conclusion was made that only the agents that act on the very early pathogenetic stages of the disease, when the damage of cholinergic neurons is not observed, can be efficient for pharmacotherapeutic intervention of MCI. Therefore, the focused search and design of “disease-modifying” medicines should be accepted as the most (and may be the only) efficient strategy for treatment and prevention of MCI.
AB - Alzheimer disease (AD) and related forms of dementia are among the main medical and social problems in the economically developed countries. It is connected with significant increase in human life span in these regions and with the absence of efficient medicines for treatment and prevention of such diseases. Lack of positive results in the developing of novel drugs for AD treatment stimulates special attention on problem of early diagnosis and drug discovery for pharmacotherapy on the very early stages of dementia, in particular, on mild cognitive impairments (MCI) due to AD. Here we review the state of art in the field of MCI diagnostics and analyze the data on the pharmacological agents developed for MCI treatment, which currently are in preclinical and clinical trials. The conclusion was made that only the agents that act on the very early pathogenetic stages of the disease, when the damage of cholinergic neurons is not observed, can be efficient for pharmacotherapeutic intervention of MCI. Therefore, the focused search and design of “disease-modifying” medicines should be accepted as the most (and may be the only) efficient strategy for treatment and prevention of MCI.
KW - Alzheimer's disease
KW - Clinical trial and AD treatment
KW - Disease-modifying drugs
KW - Multitargeting compounds
KW - Neurodegenerative disease
KW - Repositioning of old drugs
UR - http://www.scopus.com/inward/record.url?scp=85035001509&partnerID=8YFLogxK
U2 - 10.1016/j.phrs.2017.11.021
DO - 10.1016/j.phrs.2017.11.021
M3 - Review article
C2 - 29170097
AN - SCOPUS:85035001509
SN - 1043-6618
VL - 129
SP - 216
EP - 226
JO - Pharmacological Research
JF - Pharmacological Research
ER -